
    poor recruitment
  
['leukemia, chronic myeloid', 'myelodysplastic syndromes', 'leukemia, myeloid, chronic, atypical, bcr-abl negative']
['busulfan', 'fludarabine monophosphate', 'tacrolimus', 'mycophenolate mofetil', 'cyclophosphamide', 'thymoglobulin']

        Inclusion Criteria:

          -  Patients must have an indication for allogeneic hematopoietic stem cell
             transplantation

          -  Diagnosis: Chronic myeloid leukemia Myelodysplastic Syndromes Myeloprolipherative
             neoplsm unclassified Atypical chronic myelogenous leukemia

          -  Signed informed consent

          -  Patients with 10/10 HLA-matched unrelated donor available. The donor and recipient
             must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and
             HLA-DQB1. Mismatches in these loci are not allowed.

          -  Peripheral blood stem cells as graft source

          -  No second tumors

          -  No prior history of Thymoglobulin exposure or no history of anaphylactic shock after
             Thymoglobulin administration

          -  No severe concurrent illness

        Exclusion Criteria:

          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction <50%

          -  Moderate or severe decrease in pulmonary function, FEV1 <70% or DLCO<70% of predicted

          -  Respiratory distress >grade I

          -  Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper
             normal limits, creatinine >2 upper normal limits

          -  Creatinine clearance < 60 mL/min

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Requirement for vasopressor support at the time of enrollment

          -  Karnofsky index <30%

          -  Pregnancy

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      